First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced CancersBranimir I. Šikić, Sukhmani K. Padda, George A. Fisher et al.|Journal of Clinical Oncology|2019Cited by 590
Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasionNian Jiang, Jian Jian Li, Bowen Xie et al.|Nature Communications|2022Cited by 243
CPT1A/2-Mediated FAO Enhancement—A Metabolic Target in Radioresistant Breast CancerShujun Han, Jian Jian Li, Ryan Wei et al.|Frontiers in Oncology|2019Cited by 169
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cellsDemet Candas-Green, Jian Jian Li, Bowen Xie et al.|Nature Communications|2020Cited by 146
Single-intraosseous simvastatin injection suppresses cancers via activating CD8+ T cellsWanqiong Yuan, Chunli Song, Xiaoqing Ren et al.|Biomedicine & Pharmacotherapy|2022Cited by 27